Tiziana Life Sciences is showcasing its ongoing Phase 2a BANYAN Clinical Trial investigating intranasal foralumab, a fully human anti-CD3 monoclonal antibody, at ALS Nexus 2026. The presentation highlights the potential impact of innovative immunomodulation therapies in addressing ALS.
Subscribe
Biotechnology
Chronic Illness Management
Therapy Options
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
Key Takeaways:
- Tiziana Life Sciences advances immunomodulation therapy for ALS.
- Intranasal foralumab uses a fully human, anti-CD3 monoclonal antibody.
- The Phase 2a BANYAN Clinical Trial is part of the Healey ALS MyMatch program.
- The poster presentation takes place on August 24, 2026, at the Hyatt Regency Grand Cypress Resort.
- Tiziana trades on Nasdaq under TLSA.
Tiziana’s Focus on Immunomodulation
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is forging ahead in the search for novel ALS treatments through immunomodulation. Their lead development candidate, intranasal foralumab, aims to regulate the immune system by targeting key pathways involved in the progression of neurodegenerative diseases.
Introducing Intranasal Foralumab
At the heart of Tiziana’s research lies a fully human, anti-CD3 monoclonal antibody administered intranasally. This technology underscores a commitment to devising therapies that could potentially slow or alter the course of ALS by mitigating harmful immune responses.
Phase 2a BANYAN Clinical Trial
The clinical study, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” is an important step toward validating foralumab’s efficacy and safety. As part of the Healey ALS MyMatch program, the trial underscores the growing collaborations within the ALS research community, driving shared knowledge and resource exchange.
Poster Presentation Details
During ALS Nexus 2026, Dr. Pinar Uysal will present Tiziana’s latest findings in a poster session. Below is a brief overview of the event details:
| Event Name | ALS Nexus 2026 |
|---|---|
| Presentation Title | Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial |
| Date & Time | Monday, August 24, 2026, 4:30–6:30 p.m. ET |
| Location | Nexus Pavilion, Hyatt Regency Grand Cypress Resort, Orlando, Florida |
Attendees at the Nexus Pavilion will have the opportunity to learn more about the study’s background, patient enrollment strategies, and early observations related to intranasal foralumab’s potential impact on ALS.
Significance for the ALS Community
With limited treatment options available for patients, ALS research remains a critical priority. Tiziana’s trial could mark a major development in disease management, relying on a targeted immunomodulation approach intended to slow or moderate neurological decline. While more research and data are needed to confirm these advantages, the anticipation around results underscores the crucial role of robust clinical trials in shaping future therapies.
Looking Ahead
As Tiziana Life Sciences pursues new frontiers in ALS treatment, the implications are far-reaching not only for those battling the disease but for the broader medical community seeking innovative approaches to complex disorders. The Phase 2a BANYAN Clinical Trial will provide valuable insights, and the ongoing conversation at events like ALS Nexus 2026 continues to foster hope for improved outcomes in this challenging area of neurology.
